Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.33 (100.80% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Piper Jaffray Cos.Reiterated RatingOverweight$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Stifel NicolausReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Maxim GroupReiterated RatingBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016HC WainwrightReiterated RatingBuy$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Brean CapitalLower Price TargetBuy$20.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.14)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.19)($0.18)$1.80 million$3.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
DateHeadline
07/22/16 04:34 PMTrading Examination: Performance check on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - TGP
07/22/16 04:34 PMInvestor Attention Turning to Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Engelwood Daily
07/22/16 04:34 PMTalking Trading: Active Stock Rundown for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/22/16 04:34 PMEarly Session Gainers: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), American Airlines Group Inc. (NASDAQ:AAL ... - KC Register
07/22/16 04:34 PMNew Broker Ratings For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - FTSE News
07/22/16 07:36 AMInovio Pharmaceuticals, Inc. (NASDAQ:INO): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/21/16 10:41 AMInovio Pharmaceuticals, Inc. (NASDAQ:INO) Current Analyst Ratings - Fiscal Standard
07/20/16 02:40 PMAnalysts Chiming in on Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/20/16 02:40 PMWill Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Surprise Analysts? - Investor Newswire
07/20/16 07:41 AMStock Moving Lower for the Month; Investor Update on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Engelwood Daily
07/20/16 07:41 AMEquity Roundup: Stock Performance Focus on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/19/16 04:47 PMSession Focus - Highlighting Shares of: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - TGP
07/19/16 10:45 AMShare Performance Summary for: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/19/16 10:45 AMConsensus Analyst Target Price Check for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/19/16 10:45 AMEarnings Focus and Crowd Sourced Sentiment Review for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - TGP
07/19/16 10:45 AMInovio Pharmaceuticals Inc versus Merrimack Pharmaceuticals Inc Head to Head Compare - CML News
07/17/16 04:10 PMTrading Focus on Shares of: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - TGP
07/17/16 04:10 PMInovio Pharmaceuticals, Inc. (NASDAQ:INO) Earnings Review and Target Watch - TGP
07/17/16 09:02 AMShares Experiencing a Downtrend: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - TGP
07/16/16 08:00 AMInovio Pharma deploys DNA-based monoclonal antibody technology in quest to cure HIV
07/15/16 08:18 AMInovio Pharmaceuticals, Inc. (NASDAQ:INO) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 08:18 AMIntraday Active Biotech Stocks News: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Gilead Sciences Inc. (NASDAQ:GILD) - The Voice Registrar
07/15/16 08:18 AMA Timeline Of The Zika Virus Spread - Benzinga
07/15/16 08:18 AMCompany Update (NASDAQ:INO): Inovio Pharmaceuticals Inc Deploys DNA-based Monoclonal Antibody Technology ... - Smarter Analyst
07/14/16 08:22 AMWhy Inovio Pharmaceuticals' Stock Plunged in June -
07/14/16 08:08 AMAnalyst Target and Average Rating Watch: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/14/16 08:08 AMInsiders Increasing Positions in: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/14/16 08:08 AMInovio Pharma (INO) to Deploy DNA-Based Monoclonal Antibody Tech to Combat HIV Virus - StreetInsider.com
07/14/16 08:08 AMTraders Spotlight: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) , Nektar Therapeutics (NASDAQ:NKTR) - Street Updates
07/14/16 07:38 AMInovio Deploys DNA-based Monoclonal Antibody Technology in Quest to Cure HIV - [at noodls] - Funding for Potential Breakthrough Therapy is Part of Prestigious NIH/Delany Grant for Industry-Academic Collaboration PLYMOUTH MEETING, Pa., July 14, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. ...
07/14/16 07:05 AM8:05 am Inovio Pharma announces The Wistar Institute, a co collaborator, received a $23 mln grant for HIV research from the NIH -
07/13/16 05:00 PMCould Inovio Pharmaceuticals Inc Change Direction After Today's Huge Decline? - Consumer Eagle
07/13/16 05:00 PMStocks Movements to Focus: Skyline Medical Inc. (NASDAQ:SKLN) , Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Street Updates
07/12/16 04:53 PMHC Stocks Newsbeat: XOMA Corp (NASDAQ:XOMA), Inovio Pharmaceuticals Inc (NASDAQ:INO) - share market updates (press release)
07/12/16 04:53 PMAnalyst's Overview of Two Stocks: Perrigo Company (NYSE:PRGO) , Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Street Updates
07/12/16 04:53 PMBetter Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc. - Motley Fool
07/12/16 02:59 PMBetter Buy: Medivation, Inc. vs. Inovio Pharmaceuticals, Inc. -
07/12/16 09:00 AMTarget Tracker and Earnings View for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/11/16 04:43 PMInovio Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/11/16 11:53 AMUtah Sees First Zika-Related Death In Continental U.S. -
07/11/16 09:22 AMIs $31 Within Reach For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)? - Investor Newswire
07/11/16 09:22 AMImpact Score and Stock Sentiment Outlook :Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/11/16 09:22 AMStock Performance Rundown on: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/11/16 09:22 AMNext Weeks Broker Price Targets For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Fiscal Standard
07/11/16 09:22 AMBiotechnology Stocks Under the Scanner -- PTC Therapeutics, Inovio Pharma, VIVUS, and Spectrum Pharma - PR Newswire (press release)
07/08/16 07:31 AMThis Has Been the Primary Catalyst Pushing Inovio Pharmaceuticals, Inc. Up 46% in 2016 - Motley Fool
07/07/16 04:43 PMHC Stocks Review: Inovio Pharmaceuticals Inc (NASDAQ:INO), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release)
07/07/16 04:43 PMTrading Update: Share Performance Recap for Inovio Pharmaceuticals, Inc. (NASDAQ:INO) - Press Telegraph
07/07/16 04:43 PMThis Has Been the Primary Catalyst Pushing Inovio Pharmaceuticals, Inc. Up 46% in 2016 - Bloomington Pantagraph
07/07/16 07:34 AMInovio Pharmaceuticals (INO) : Analyst Rating Update - Trade Calls

Social

About Inovio Pharmaceuticals

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: INO
  • CUSIP:
Key Metrics:
  • Previous Close: $9.13
  • 50 Day Moving Average: $9.78
  • 200 Day Moving Average: $8.42
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $667.38M
  • Beta: 2.6
  • Current Year EPS Consensus Estimate: $-0.92 EPS
  • Next Year EPS Consensus Estimate: $-1.16 EPS
Additional Links:
Inovio Pharmaceuticals (NASDAQ:INO) Chart for Monday, July, 25, 2016